Live Breaking News & Updates on Tissue Specific Therapeutic

Stay updated with breaking news from Tissue specific therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board

Dr. Liedtke joins Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Stanford University Medical CenterDr. Liedtke is a recognized thought leader in. ....

Stanford University , United States , Medizinische Hochschule Hannover , Michaela Liedtke , Gabriel Morris , Ilya Rachman , Los Angeles , Mike Moyer , Stanford Cardiovascular Institute , Translational Research Award , Oncology Group , Stanford University Medicine Cancer Center Program , American Society Of Hematology , Lymphoma Research Foundation , Immix Biopharma Inc , American Society Of Clinical Oncology , International Myeloma Society , Company Contact , International Society Of Amyloidosis , Doris Duke Foundation , Stanford Amyloid Center , Stanford Department Of Medicine , Young Adult Program , Stanford University Medical Center , Memorial Sloan Kettering Cancer Center , Methods In Clinical Cancer Research Scholar ,

Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Successful completion supports expansion of its ongoing NEXICART-1 NXC-201 CAR-T clinical trial to the U.S.NXC-201 is manufactured at our state-of-the-art cellular immunotherapy manufacturing. ....

United States , Los Angeles , Gabriel Morris , Mike Moyer , Ilya Rachman , Immix Biopharma Inc , Exchange Commission , Nexcella Inc , Company Contact , Chief Executive Officer , Chief Financial Officer , Immix Biopharma , Orphan Drug Designation , Tissue Specific Therapeutic , Rare Pediatric Disease Designation , Risk Factor , Annual Report ,

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

100% (9/9) overall response rate and 67% (6/9) complete response rate (MRD 10-5) observed in heavily pre-treated patients with daratumumab relapse. ....

United States , Grand View , Iiia Iiib , Mike Moyer , Gabriel Morris , Polina Stepensky , Los Angeles , Ilya Rachman , Exchange Commission , International Myeloma Society Annual Meeting , Immix Biopharma Inc , International Myeloma Working Group , International Myeloma Society Annual , Nexcella Inc , Company Contact , View Research , Hadassah Medical Organization , Bone Marrow Transplantation , Chief Executive Officer , Chief Financial Officer , Immix Biopharma , Biopharma Announces Complete Response , Uniform Response , Orphan Drug Designation , Tissue Specific Therapeutic , Rare Pediatric Disease Designation ,

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

100% overall response rate and 67% complete response rate observed in heavily pre-treated patients with daratumumab relapsed/refractory AL Amyloidosis as of the September 20, 2023 data cutoff100% . ....

Grand View , United States , Mike Moyer , Gabriel Morris , Polina Stepensky , Iiia Iiib , Ilya Rachman , Los Angeles , International Myeloma Society Annual Meeting , Hadassah Medical Organization , Department Of Bone Marrow Transplantation , International Myeloma Working Group , International Myeloma Society Annual , Globenewswire Inc , Company Contact , Immix Biopharma Inc , Nexcella Inc , View Research , Exchange Commission , Bone Marrow Transplantation , Chief Executive Officer , Chief Financial Officer , Biopharma Announces Complete Response , Myeloma Society Annual Meeting , Myeloma Working Group , Uniform Response ,

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma 95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. Median progression free survival (mPFS) was 12.9 months as of the July 17, 2023 data cut-of ....

United States , Polina Stepensky , Gabriel Morris , Los Angeles , Ilya Rachman , Mike Moyer , Immix Biopharma Inc , International Myeloma Working Group , International Myeloma Society Annual Meeting , Exchange Commission , Nexcella Inc , Immix Biopharma Announces , Annual Meeting , Overall Response Rate , Leading Response Rate , Hadassah Medical Organization , Bone Marrow Transplantation , Chief Financial Officer , Chief Executive Officer , Biopharma Announces , Uniform Response , Multiple Myeloma , Immix Biopharma , Orphan Drug Designation , Tissue Specific Therapeutic , Rare Pediatric Disease Designation ,